Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12806081 | 0.83 | GABRA1 (0.64) | IDO1TAAR1CA12CA1CA2 | |
| SCHEMBL31200741 | 0.83 | GABRA1 (0.64) | IDO1TAAR1CA12CA1CA2 | |
| SCHEMBL31614197 | 0.82 | IDO1 (0.41) | IDO1TAAR1CA12CA1CA2 | |
| SCHEMBL7674880 | 0.82 | GABRA1 (0.45) | IDO1TAAR1CA12CA1CA2 | |
| SCHEMBL7674886 | 0.82 | PDE4A (0.44) | IDO1TAAR1CA12CA1CA2 | |
| SCHEMBL27761667 | 0.82 | TAAR1 (0.50) | IDO1TAAR1CA12CA1CA2 | |
| SCHEMBL29377714 | 0.80 | IDO1 (0.57) | IDO1TAAR1CA12CA1CA2 | |
| SCHEMBL17804 | 0.80 | IDO1 (0.57) | IDO1TAAR1CA12CA1CA2 | |
| SCHEMBL1501174 | 0.79 | CA1 (0.58) | CA12CA1CA2CA4CA7 | |
| SCHEMBL216572 | 0.79 | SMN1; SMN2 (0.50) | CA12CA1CA2CA14MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860975-B1 | MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-3860975-B1 | MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-10-18 | — | — | EP | disclosed |
| CN-114874233-A | chrysene derivative and application thereof | 北京八亿时空液晶科技股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-114829362-A | Six-membered and five-membered aromatic ring derivative containing nitrogen heteroatom and used as SHP2 inhibitor | 成都倍特药业股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2021115286-A1 | SIX-MEMBERED AND FIVE-MEMBERED AROMATIC RING DERIVATIVE CONTAINING NITROGEN HETEROATOMS WHICH CAN BE USED AS SHP2 INHIBITOR | 成都倍特药业股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| WO-2021115286-A1 | SIX-MEMBERED AND FIVE-MEMBERED AROMATIC RING DERIVATIVE CONTAINING NITROGEN HETEROATOMS WHICH CAN BE USED AS SHP2 INHIBITOR | 成都倍特药业股份有限公司 | 2021-06-17 | — | — | WO | disclosed |
| US-11014884-B2 | Modulators of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200140384-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-05-07 | — | — | US | disclosed |
| WO-2020072377-A1 | MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| EP-0652875-A1 | (HETERO)-ARYL KETONES DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | SMITHKLINE BEECHAM PLC (GB) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994002478-A1 | (HETERO)-ARYL KETONES DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | SMITHKLINE BEECHAM PLC (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014884-B2 | Modulators of hemoglobin | HBG1, HBG2, HBB | IDO1 4083/4885TAAR1 4836/4885CA12 1341/4885 |
| US-20200140384-A1 | MODULATORS OF HEMOGLOBIN | HBG1, HBG2, HBB | IDO1 4083/4885TAAR1 4836/4885CA12 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.